Sanofi's multiple myeloma treatment Sarclisa accepted for FDA priority review

The second most common haematologic malignancy is responsible for more than 180,000 new global diagnoses every year

Related Keywords

Dietmar Berger , Takeda Velcade , Drug Administration ,